36,484 reports of this reaction
13.1% of all DENOSUMAB reports
#1 most reported adverse reaction
OFF LABEL USE is the #1 most commonly reported adverse reaction for DENOSUMAB, manufactured by Amgen, Inc. There are 36,484 FDA adverse event reports linking DENOSUMAB to OFF LABEL USE. This represents approximately 13.1% of all 278,448 adverse event reports for this drug.
Patients taking DENOSUMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a frequently reported adverse event for DENOSUMAB, accounting for a significant proportion of all reports.
In addition to off label use, the following adverse reactions have been reported for DENOSUMAB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 36,484 FDA reports for DENOSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 13.1% of all adverse event reports for DENOSUMAB, making it one of the most commonly reported side effect.
If you experience off label use while taking DENOSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.